PARP1 was first identified as the target of ZQJ29 in the treatment of pancreatic cancer, and ZQJ29 targets PARP1 to activate TP53, thereby inhibiting the SLC7A11/GPX4 signaling pathway and promoting ferroptosis in pancreatic cancer cells. Here, PARP1 is linked to pancreatic neoplasm.